Emerging research explores how a wearable device may identify infection before symptoms appear, which treatments reduce hospitalizations, and who remains most at risk.
From respiratory syncytial virus monoclonal antibody approvals to thimerosal-free vaccine preferences, ACIP’s latest guidance has important implications for your practice.
Recent studies show distinct metabolic disruptions in children with multisystem inflammatory syndrome in children, plaque progression in adults post–COVID-19, and surprising pneumococcal risk patterns.
...
New research explores long COVID risks in children, ACIP's expanded RSV vaccine use, U.S. disease resurgence under falling immunization, and long COVID’s burden on health care workers.
In this respiratory disease roundup, researchers report on the efficacy of nirmatrelvir-ritonavir for treating Long COVID, the CDC updates recommendations on “triple threat” vaccines for respiratory virus...
The Advisory Committee on Immunization Practices released its updated annual immunization schedule for 2024 that includes new sections on respiratory syncytial virus (RSV), and the mpox (monkeypox) and...
The CDC updated its guidance due to the United States seeing fewer hospitalizations associated with COVID-19 and because there are numerous tools to combat influenza, COVID-19, and respiratory syncytial...
This COVID-19 roundup includes coverage of the FDA’s guidance for the correct Moderna vaccine dosage for pediatric patients, COVID-19 outcomes for patients with hypertension and diabetes, and the risk of...
Earlier this year, the FDA approved the same vaccine for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
